Introduction

To compare oncologic outcomes of propensity score matched (PSM) cohorts of patients treated with either ORC or RARC and intracorporeal urinary diversion (UD).

Methods

The IRB approved bladder cancer databases of two centers were queried for &[Prime]cystectomy with curative intent&[Prime]. A 1:2 PSM analysis was used to minimize the biases of retrospective analysis of data. Kaplan-Meier method was used to compare the oncologic outcomes of the PSM cohorts. Survival rates were computed at 2, 3 and 4 years after surgery and the log rank test was applied to assess statistical significance between groups. Univariable and multivariable Cox regression analyses were performed to identify predictors of disease-free survival (DFS).

Results

Overall 631 patients with a minimum 2 yr follow-up were included, (478 ORC and 153 RARC). _x000D_ Patients treated with ORC had significantly higher ASA scores (p=0.007) and pT stages (p=0.001), lower lymph node count (LNc) (p<0.001) and lesser adoption of neoadjuvant chemotherapy (p<0.001). After applying the PSM, the two groups (193 ORC, 110 RARC patients) did not differ for any clinical or pathologic variable (all p ≥0.627), except than for LNc (p=.004) (Table 1). _x000D_ At Kaplan-Meier analysis ORC and RARC cohorts displayed comparable DFS (p=0.73), cancer specific survival (p=0.7) and overall survival probabilities (p=0.12). _x000D_ At multivariable Cox regression analysis in the postPSM cohort, age (p=0.048), pT stage >2 (p=0.003) and nodal metastasis (p<0.001) were independent predictors of DFS (Table 2)._x000D_

Conclusions

RARC with intracorporeal UD and ORC provide comparable mid term oncologic outcomes.

Funding

none